PTEN and TP53/p53 in endometrial carcinoma: molecular pathways, immunohistochemistry, molecular classification, and implications for resource-constrained African settings—a scoping review

Background Endometrial carcinoma (EC) is an important gynecological malignancy worldwide, but access to molecular profiling remains limited in resource-constrained settings. PTEN loss reflects disruption of PI3K/AKT/mTOR pathway regulation, whereas p53 immunohistochemistry (IHC) provides a surrogate assessment of p53 status within molecular classification. This scoping review maps their biological, diagnostic, clinicopathological and reported prognostic associations and considers implications for African settings. Methods The review followed the Arksey and O’Malley framework, refined by Levac et al., and reported according to PRISMA-ScR. PubMed/MEDLINE, Scopus, Web of Science, Google Scholar and African Journals OnLine were searched for English-language publications from 1 January 2001 to 8 August 2026. Eighteen primary studies were synthesized descriptively. We did not conduct a formal risk-of-bias assessment or certainty-of-evidence grading. Results Included studies reported associations of PTEN loss with endometrioid tumorigenesis and of molecularly detected TP53 alterations or abnormal p53 IHC patterns with adverse clinicopathological features and, in studies assessing clinical outcomes, adverse prognostic associations. African evidence comprised Nigerian p53 data, Kenyan combined PTEN/p53/MMR IHC findings, and South African MMR and molecular-classification studies. Complete molecular classification incorporates pathogenic POLE mutation status, MMR status and p53 status; PTEN is not classification-defining, but an adjunct biomarker pending further clinical validation. Conclusion p53 IHC contributes to molecular classification but cannot replace MMR or POLE assessment. PTEN remains an adjunctive biomarker in selected diagnostic and research contexts. An author-proposed phased framework prioritizes validated histopathology and MMR/p53 IHC, referral testing and integrated reporting. This framework has not been validated by the included studies; its clinical impact, cost-effectiveness, scalability and sustainability require prospective evaluation.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-11-16
DOI
https://doi.org/10.3389/fonc.2026.1967427
Primary Topic
Endometrial and Cervical Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

PTEN and TP53/p53 in endometrial carcinoma: molecular pathways, immunohistochemistry, molecular classification, and implications for resource-constrained African settings—a scoping review

Juliet Oluchukwu Offor, Sophia George, Ayodele Omotoso, Matthew Schlumbrecht
1 links
Frontiers in Oncology
Endometrial and Cervical Cancer Treatments
article

PTEN and TP53/p53 in endometrial carcinoma: molecular pathways, immunohistochemistry, molecular classification, and implications for resource-constrained African settings—a scoping review

Juliet Oluchukwu Offor, Sophia George, Ayodele Omotoso, Matthew Schlumbrecht
article en

Abstract

Background Endometrial carcinoma (EC) is an important gynecological malignancy worldwide, but access to molecular profiling remains limited in resource-constrained settings. PTEN loss reflects disruption of PI3K/AKT/mTOR pathway regulation, whereas p53 immunohistochemistry (IHC) provides a surrogate assessment of p53 status within molecular classification. This scoping review maps their biological, diagnostic, clinicopathological and reported prognostic associations and considers implications for African settings. Methods The review followed the Arksey and O’Malley framework, refined by Levac et al., and reported according to PRISMA-ScR. PubMed/MEDLINE, Scopus, Web of Science, Google Scholar and African Journals OnLine were searched for English-language publications from 1 January 2001 to 8 August 2026. Eighteen primary studies were synthesized descriptively. We did not conduct a formal risk-of-bias assessment or certainty-of-evidence grading. Results Included studies reported associations of PTEN loss with endometrioid tumorigenesis and of molecularly detected TP53 alterations or abnormal p53 IHC patterns with adverse clinicopathological features and, in studies assessing clinical outcomes, adverse prognostic associations. African evidence comprised Nigerian p53 data, Kenyan combined PTEN/p53/MMR IHC findings, and South African MMR and molecular-classification studies. Complete molecular classification incorporates pathogenic POLE mutation status, MMR status and p53 status; PTEN is not classification-defining, but an adjunct biomarker pending further clinical validation. Conclusion p53 IHC contributes to molecular classification but cannot replace MMR or POLE assessment. PTEN remains an adjunctive biomarker in selected diagnostic and research contexts. An author-proposed phased framework prioritizes validated histopathology and MMR/p53 IHC, referral testing and integrated reporting. This framework has not been validated by the included studies; its clinical impact, cost-effectiveness, scalability and sustainability require prospective evaluation.

Frontiers in OncologyVol. 16
University of Miami (US), Sylvester Comprehensive Cancer Center (US), Federal Medical Centre Abuja (NG)
Good health and well-being
Endometrial and Cervical Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon